Cullinan Oncology to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Cullinan Oncology, Inc. (Nasdaq: CGEM) announced its participation in two investor conferences. The Morgan Stanley 19th Annual Global Healthcare Conference is scheduled from September 9-15, featuring CEO Owen Hughes in a virtual chat on September 13 at 12:30 PM ET and a corporate update at 4:15 PM ET. Additionally, at the H.C. Wainwright 23rd Annual Global Investment Conference, Chief Development Officer Jennifer Michaelson will discuss engineered cytokines on September 14 from 1:30-3:00 PM ET. Management will also engage in one-on-one meetings.

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced its participation in the following upcoming investor conferences:

• Morgan Stanley 19^th Annual Global Healthcare Conference taking place Thursday, September 9^th through Wednesday, September 15^th
  • Cullinan’s CEO, Owen Hughes, will participate in a virtual fireside chat on Monday, September 13^th, at 12:30pm ET, and will provide a corporate update at 4:15pm ET

• H.C. Wainwright 23^rd Annual Global Investment Conference on Monday, September 13^th through Wednesday, September 15^th
  • Cullinan’s Chief Development Officer of Biologics, Jennifer Michaelson, will participate in a panel discussion titled “Engineered Cytokines: The Next Big Wave in Immuno-oncology”, which will be broadcast to conference participants on Tuesday, September 14^th, from 1:30 – 3:00pm ET

Members of Cullinan’s management will be presenting virtually at each conference, as well as participating in one-on-one investor meetings. Please visit the investor section of Cullinan’s website at www.investors.cullinanoncology.com for more information.

About Cullinan Oncology

Cullinan Oncology is a biopharmaceutical company that strives to deliver results for our various stakeholders through disciplined capital allocation, decisive action, prudent risk taking and creative business development. We seek to drive shareholder returns by focusing on the patient. The Company’s strategy is to build a diversified pipeline of targeted and immuno-oncology therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes. Learn more about Cullinan at www.cullinanoncology.com.

Contacts:

Investor Relations
investors@cullinanoncology.com

Jeff Trigilio
+1 617.410.4650
jtrigilio@cullinanoncology.com

 

FAQ

What is the date for Cullinan Oncology's participation in the Morgan Stanley conference?

Cullinan Oncology will participate in the Morgan Stanley 19th Annual Global Healthcare Conference from September 9-15, 2021.

Who will represent Cullinan Oncology at the Morgan Stanley conference?

CEO Owen Hughes will represent Cullinan Oncology at the Morgan Stanley conference.

When is the virtual chat with Owen Hughes scheduled?

Owen Hughes' virtual chat is scheduled for September 13, 2021, at 12:30 PM ET.

What topic will Jennifer Michaelson discuss at the H.C. Wainwright conference?

Jennifer Michaelson will discuss engineered cytokines in a panel at the H.C. Wainwright conference on September 14, 2021.

What is Cullinan Oncology's stock symbol?

Cullinan Oncology's stock symbol is CGEM.